Mazor Robotics Ltd. (MZOR) Reaches $60.63 After 9.00% Down Move; Shorts at Eiger Biopharmaceuticals (EIGR) Lowered By 18.45%

April 17, 2018 - By Ellis Scott

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) had a decrease of 18.45% in short interest. EIGR’s SI was 289,500 shares in April as released by FINRA. Its down 18.45% from 355,000 shares previously. With 75,000 avg volume, 4 days are for Eiger Biopharmaceuticals Inc (NASDAQ:EIGR)’s short sellers to cover EIGR’s short positions. The SI to Eiger Biopharmaceuticals Inc’s float is 4.69%. The stock increased 0.91% or $0.1 during the last trading session, reaching $11.1. About 124,494 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has declined 11.57% since April 17, 2017 and is downtrending. It has underperformed by 23.12% the S&P500.

The stock of Mazor Robotics Ltd. (NASDAQ:MZOR) is a huge mover today! The stock decreased 1.65% or $1.02 during the last trading session, reaching $60.63. About 213,254 shares traded. Mazor Robotics Ltd. (NASDAQ:MZOR) has risen 109.51% since April 17, 2017 and is uptrending. It has outperformed by 97.96% the S&P500.The move comes after 9 months negative chart setup for the $1.65B company. It was reported on Apr, 17 by We have $55.17 PT which if reached, will make NASDAQ:MZOR worth $148.68 million less.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $116.85 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

Among 7 analysts covering Mazor Robotics (NASDAQ:MZOR), 2 have Buy rating, 3 Sell and 2 Hold. Therefore 29% are positive. Mazor Robotics has $67.0 highest and $23 lowest target. $39’s average target is -35.68% below currents $60.63 stock price. Mazor Robotics had 17 analyst reports since November 20, 2015 according to SRatingsIntel. Wells Fargo upgraded the shares of MZOR in report on Thursday, May 19 to “Outperform” rating. B. Riley & Co initiated it with “Buy” rating and $25 target in Friday, October 7 report. Barclays Capital maintained it with “Overweight” rating and $23 target in Thursday, July 14 report. As per Tuesday, May 31, the company rating was downgraded by Sterne Agee CRT. The stock of Mazor Robotics Ltd. (NASDAQ:MZOR) earned “Hold” rating by Needham on Thursday, October 5. The rating was upgraded by Sterne Agee CRT to “Buy” on Friday, November 20. Barclays Capital downgraded Mazor Robotics Ltd. (NASDAQ:MZOR) rating on Thursday, October 19. Barclays Capital has “Sell” rating and $34.0 target. As per Monday, October 30, the company rating was maintained by Ladenburg. The rating was maintained by Needham on Thursday, July 6 with “Hold”. The firm earned “Buy” rating on Friday, July 8 by Standpoint Research.

Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. The company has market cap of $1.65 billion. The firm operates in the field of image guided surgery and computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness. It currently has negative earnings. It offers Mazor X surgical guidance system and Renaissance surgical guidance system that transform spine surgery from freehand procedures to guided procedures.

Mazor Robotics Ltd. (NASDAQ:MZOR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: